Edition:
India

People: Neurotrope Inc (NTRP.OQ)

NTRP.OQ on NASDAQ Stock Exchange Capital Market

5.91USD
12:11am IST
Change (% chg)

$0.09 (+1.55%)
Prev Close
$5.82
Open
$5.94
Day's High
$6.01
Day's Low
$5.89
Volume
4,403
Avg. Vol
18,376
52-wk High
$11.90
52-wk Low
$3.34

Trzepacz, Paula 

Dr. Paula T. Trzepacz is Executive Vice President and Chief Medical Officer of the Company. Prior to joining Neurotrope, Dr. Trzepacz was at Eli Lilly and Company for over 15 years where she was most recently a Senior Medical Fellow in Neurosciences drug development. She served on the global drug development team for Amyvid, the PET radiotracer indicated for estimation of beta-amyloid plaque density in brains of cognitively impaired persons suspected of having Alzheimer's disease. Prior to that, she led the Phase 2 medical team investigating mibampator, a novel AMPA receptor potentiator, for agitation and aggression in Alzheimer's disease patients. As Senior Medical Fellow on the global Strattera team for over three years Dr. Trzepacz was the medical lead for registration and regulatory related issues for its Attention Deficit Hyperactivity Disorder indications for both adult and pediatric populations, including design of new Phase 3 registration trials and collaborations with the European and Japanese Lilly teams. As Senior Medical Director of U.S. Neurosciences, she was responsible for a large medical team of physicians and other scientists including for the design and execution of many Phase 4 double-blind, randomized placebo-controlled clinical trials over a five year period. Some of those trials were used to support registration work in addition to answering key patient-relevant questions for practicing physicians. Importantly, the products her team supported included Prozac, Zyprexa, Cymbalta, and Strattera and their multiple indications, line extensions, and formulations.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --